Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience.

Saved in:

Bibliographic Details
Title:	Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience.
Authors:	Choucair K; Karmanos Cancer Institute, Wayne State University, Detroit, MI., Page SJ; Cancer Center of Kansas, Wichita, KS., Mattar BI; Cancer Center of Kansas, Wichita, KS., Dakhil CS; Cancer Center of Kansas, Wichita, KS., Nabbout NH; Cancer Center of Kansas, Wichita, KS., Deutsch JM; Cancer Center of Kansas, Wichita, KS., Truong QV; Cancer Center of Kansas, Wichita, KS., Truong PV; Cancer Center of Kansas, Wichita, KS., Moore DF Jr; Cancer Center of Kansas, Wichita, KS., Cannon MW; Cancer Center of Kansas, Wichita, KS., Kallail KJ; Kansas University School of Medicine, Wichita, KS., Moore JA; Cancer Center of Kansas, Wichita, KS., Dakhil SR; Cancer Center of Kansas, Wichita, KS., Diab R; Kansas University School of Medicine, Wichita, KS., Kamran S; Kansas University School of Medicine, Wichita, KS., Reddy PS; Cancer Center of Kansas, Wichita, KS; Kansas University School of Medicine, Wichita, KS. Electronic address: pavansreddy@gmail.com.
Source:	Clinical breast cancer [Clin Breast Cancer] 2023 Feb; Vol. 23 (2), pp. 155-161. Date of Electronic Publication: 2022 Nov 23.
Publication Type:	Journal Article
Journal Info:	Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1938-0666
DOI:	10.1016/j.clbc.2022.11.005